SCHEMBL3662225

SCHEMBL3662225

CCCCCCCCCCCCCCCCC(=O)OC(C)(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.57
LMNA P02545 2/20 0.53
PAM P19021 2/20 0.52
CES2 O00748 3/20 0.50
CES1 P23141 3/20 0.50
MAPT P10636 2/20 0.50
MAPK1 P28482 1/20 0.50
TSHR P16473 5/20 0.48
PPARG P37231 6/20 0.48
PPARD Q03181 6/20 0.48
PPARA Q07869 6/20 0.48
HDAC11 Q96DB2 5/20 0.48
GPR84 Q9NQS5 4/20 0.48
ALDH1A1 P00352 2/20 0.48
TLR2 O60603 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
FABP4 P15090 2/20 0.48
PTPN1 P18031 2/20 0.48
SLC22A6 Q4U2R8 1/20 0.48
SLC22A8 Q8TCC7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3658855 1.00 DGKA (0.57) DGKALMNAPAMCES2CES1
SCHEMBL3823631 1.00 DGKA (0.57) DGKALMNAPAMCES2CES1
SCHEMBL2918263 1.00 DGKA (0.57) DGKALMNAPAMCES2CES1
SCHEMBL9768598 1.00 DGKA (0.57) DGKALMNAPAMCES2CES1
SCHEMBL5732818 1.00 DGKA (0.57) DGKALMNAPAMCES2CES1
SCHEMBL7771101 1.00 DGKA (0.57) DGKALMNAPAMCES2CES1
SCHEMBL3121472 1.00 DGKA (0.57) DGKALMNAPAMCES2CES1
SCHEMBL9985650 1.00 DGKA (0.57) DGKALMNAPAMCES2CES1
SCHEMBL62214 1.00 DGKA (0.57) DGKALMNAPAMCES2CES1
SCHEMBL1510009 1.00 DGKA (0.57) DGKALMNAPAMCES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113754753-B Synthetic method of somalupeptide 深圳翰宇药业股份有限公司 2024-09-03 CN disclosed
CN-101932601-B Insulin derivates 诺沃-诺迪斯克有限公司 2016-08-03 CN disclosed
CN-101784562-B There is the insulin analog of acyl group and aklylene glycol moiety 诺沃-诺迪斯克有限公司 2016-07-13 CN disclosed
CN-101133082-B ACYLATED GLP-1 COMPOUNDS NOVO NORDISK A/S (DK) 2016-01-13 CN disclosed
CN-105154498-A Semi-recombinant preparation of GLP-1 analogues NOVO NORDISK AS 2015-12-16 CN disclosed
EP-2217621-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2015-04-22 EP disclosed
CN-104402989-A ACYLATED GLP-1 COMPOUNDS NOVO NORDISK AS 2015-03-11 CN disclosed
CN-101784563-B Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids NOVO NORDISK AS 2015-02-04 CN disclosed
CN-104185639-A GLP-1 prodrugs NOVO NORDISK AS 2014-12-03 CN disclosed
CN-104017062-A Acylated GLP-1 compounds NOVO NORDISK AS 2014-09-03 CN disclosed
CN-102333788-A Modification of factor viii NOVO NORDISK AS 2012-01-25 CN disclosed
CN-101932601-A Insulin derivative NOVO NORDISK AS 2010-12-29 CN disclosed
CN-101910193-A Semi-recombinant preparation method of GLP-1 analogue NOVO NORDISK AS 2010-12-08 CN disclosed
EP-2217621-A1 INSULIN DERIVATIVE Novo Nordisk A/S (DK) 2010-08-18 EP disclosed
CN-101784563-A insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids NOVO NORDISK AS 2010-07-21 CN disclosed
WO-2009060071-A1 INSULIN DERIVATIVE NOVO NORDISK A/S (DK) 2009-05-14 WO disclosed
EP-2058330-A1 Insulin derivative NOVO NORDISK A/S (DK) 2009-05-13 EP disclosed
CN-101133082-A Acylated GLP-1 compounds NOVO NORDISK AS (DK) 2008-02-27 CN disclosed